Key result
Tailoring antihypertensive therapy with beta-blockers or calcium channel blockers remains essential for concomitant CV disease.
Answers are grounded in this paper and cite their sources.
Antihypertensive therapy must be tailored in patients with concomitant cardiovascular disease, with beta-blockers and calcium channel blockers frequently being appropriate choices.
Many drugs for the treatment of hypertension are available in the United States today. Of the various factors that determine the appropriate treatment for a particular patient, the presence of concomitant heart disease requires specific tailoring of the antihypertensive therapy. Coronary artery disease, aortic insufficiency, congestive heart failure, left ventricular hypertrophy, premature ventricular contractions, supraventricular arrhythmias, mitral valve prolapse, orthostatic hypotension, and aortic dissection are some of the conditions that influence the choice of treatment. Diabetes places hypertensive patients at increased risk of heart disease, and exercise and sexual function are other considerations that govern the selection of treatment for the hypertensive person. For all of these conditions, more than one drug choice is often possible, but usually hypertensive patients can be treated with a beta-blocker or a calcium channel blocker in these special circumstances.
No takes yet. Share an insight, caveat, or question.
Charles P. Tifft (1988) conducted a review in Hypertension with concomitant cardiovascular disease. Antihypertensive therapy (beta-blockers or calcium channel blockers) was evaluated. Tailoring antihypertensive therapy, often with beta-blockers or calcium channel blockers, is required for hypertensive patients with concomitant cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: